Operator
Welcome to the convention name. [Operator Instructions] Now I’ll hand the convention over to the audio system. Please go forward.
Nikolaj Sørensen
President & CEO
Thanks very a lot, and welcome to this name updating you concerning the transaction that we accomplished yesterday night. And first, I simply wish to prolong my apologies for disturbing you right here on the twenty third of December, the place most of you most likely wish to go Christmas purchasing or beginning the holiday. However for us, it is a main step and one thing we have been working intensively on all through the autumn and that we’re now capable of shut this transaction simply earlier than Christmas could be very welcome, and we expect is the appropriate factor for Orexo to do in our present state.
So we offers you an replace about our settlement that we reached with Dexcel Pharma yesterday night, the place we’re divesting the U.S. rights to Zubsolv and we’ll present a bit extra particulars on it, however most of it’ll, in fact, be anchored within the press launch that now we have made yesterday night. So shortly concerning the transaction, now we have offered the rights to Zubsolv within the U.S. to Dexcel for a web quantity of $91 million. We may even be paid for the stock that now we have at closing.
As well as, there’s an settlement that we’ll have a contingent cost or an earn-out, you’ll be able to say, which may very well be as much as $16.8 million that shall be paid out
